Fertility preservation treatment in patients with epithelial ovarian cancer

WANG Xin-yu,XIE Xing

2012-01-01

Abstract:Early epithelial ovarian cancer possesses good prognosis.Preservation of reproductive ability is one of treatment options for young and willing fertility-sparing patients.However,indication and treatment protocol should be abided to obtain ideal prognostic and pregnant outcomes.

What problem does this paper attempt to address?

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

Xiao-mei Tong,Xiao-na Lin,Hong-fei Jiang,Ling-ying Jiang,Song-ying Zhang,Feng-bing Liang

IF: 6.133

2013-01-01

Chinese Medical Journal

Abstract:OBJECTIVE:This study aimed to review the available literature on fertility-preserving treatment and pregnancy outcomes in patients with early-stage endometrial carcinoma who desired to preserve their fertility.DATA SOURCES:The PubMed database (1992-2012) was searched for the words "conservative "OR" fertility sparing "OR" fertility preserving" AND "endometrial neoplasms" (MeSH). All relevant articles in English and the relevant references were collected.STUDY SELECTION:Data from published articles about fertility-preserving treatment of endometrial cancer, including the response and recurrence rate of conservative treatment, strategies of infertility treatment, pregnancy, and obstetric outcomes, were selected. Data were mainly extracted from 41 studies, which are listed in the reference section of this review.RESULTS:Hormone therapy was the most common method used for early-stage endometrial carcinoma in patients who wished to preserve fertility. Sixty percent of the patients became pregnant after remission of the carcinoma. The percentage of patients who conceived in the assisted reproductive technology group was higher than that of the natural pregnancy group (80.0% vs. 43.2%, P < 0.01). A higher rate of preterm labor and multiple pregnancies was observed in the assisted reproductive technology group than that in the natural pregnancy group. The majority of pregnancies (71.4%) in the assisted reproductive technology group were achieved by in vitro fertilization-embryo transfer. The clinical pregnancy rate of transfer cycles in patients with endometrial carcinoma was 34.1%.CONCLUSIONS:Assisted reproductive technology is a good option in well-selected patients with early-stage endometrial carcinoma who have completed conservative treatment. In vitro fertilization-embryo transfer offers an opportunity to achieve an immediate pregnancy.
Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant—a Chinese retrospective cohort study among 148 cases

Bin Yang,Yan Yu,Jing Chen,Yan Zhang,Ye Yin,Nan Yu,Ge Chen,Shifei Zhu,Haiyan Huang,Yongqun Yuan,Jihui Ai,Xinyu Wang,Kezhen Li

DOI: https://doi.org/10.1007/s11684-017-0554-3

2017-01-01

Frontiers of Medicine

Abstract:This study was performed to evaluate the oncological and reproductive outcomes of childbearing-age women treated with fertility-sparing surgery (FSS) for non-epithelial ovarian tumors in China. One hundred and forty eight non-epithelial ovarian tumor women treated with FSS between January 1, 2000 and August 31, 2015 from two medical centers in China were identified. Progression-free survival (PFS) was 88.5%, whereas overall survival (OS) was 93.9%. Univariate analysis suggested that delivery after treatment is related to PFS ( P = 0.023), whereas histology significantly influenced OS. Cox regression analysis suggested that only histology was associated with PFS and OS ( P < 0.05). Among the 129 women who completed adjuvant chemotherapy (ACT), none developed amenorrhea. Among the 44 women who desired pregnancy, 35 (79.5%) successfully had 51 gestations including 35 live births without birth defects. Non-epithelial ovarian tumors can achieve fulfilling prognosis after FSS and chemotherapy. Histology might be the only independent prognostic factor for PFS and OS. FSS followed by ACT appeared to have little or no effect on fertility. Meanwhile, postoperative pregnancy did not increase the PFS or OS. Use of gonadotropin-releasing hormone agonist was not beneficial for fertility.
Fertility Preservation in Young Female Cancer Patients

YAN Jie,QIAO Jie

DOI: https://doi.org/10.3969/j.issn.1674-1889.2011.04.004

2011-01-01

Abstract:The improvement of radiotherapy and chemotherapy results in the increases in young cancer survival rates.Unfortunately,many of the treatments are toxic to the ovarian function,finite supply of oocytes and diminish a woman's chance of future childbearing.Young female cancer survivors have put added emphasis on the need for fertility preservation services.Assisted reproductive techniques(ART) and fertility-sparing surgery are currently available options to increase the likelihood of childbearing after cancer treatment.The currently available options for fertility preservation should be discussed with every patient who is in their reproductive years prior to initiating any treatments.Fertility preservation strategies and protocols should be discussed and performed individually to every cancer patient.As a result,survivors of breast cancer,lymphoma and some ovarian tumors could obtain their child currently.Reproductive clinicians should work closely with oncologists to counsel patients about the treatment on their future fertility and discuss options to preserve potential fertility before starting treatments.Greater emphasis should therefore be placed on fertility preservation during the cancer treatment planning process.
Feasibility and Safety of Fertility Preservation Surgery in Female Patients with Early Epithelial Ovarian Cancer

ZHAI Qing-zhi,YE Ming-xia,PENG Hong-mei,SONG Lei,ZHAO En-feng,MENG Yuan-guang,YAO Yuan-qing

DOI: https://doi.org/10.3969/j.issn.2095-5227.2013.08.003

2013-01-01

Abstract:Objective To study the feasibility and safety of fertility-preserving surgery in female patients with early epithelial ovarian cancer.Methods Clinical data about 35 female patients with early epithelial ovarian cancer who underwent fertilitypreserving surgery in our hospital from January 2008 to June 2012 were retrospectively analyzed.Results Of the 35 patients with early epithelial ovarian cancer,10 were diagnosed as stageⅠa,14 as stageⅠb,and 11 as stageⅠc according to the International Federation of Gynecology and Obstetrics(FIGO) criteria,4 underwent unilateral adnexectomy and 9 received operation by stages.Five patients had relapse and 2 patients delivered 2 healthy babies after operation.Conclusion Fertility-preserving surgery can be performed in female patients with early epithelial ovarian cancer.The patients should be closely followed up after operation.
Fertility-preserving treatment for young women with early-stage endometrial cancer

Shiqian ZHANG,Hao YU

DOI: https://doi.org/10.19538/j.fk2017050106

2017-01-01

Abstract:With the delay of pregnancy age,there is an increasing likelihood of raised percentage of young females with early-stage endometrial cancer.Considering the favourable prognostic features,such as focal lesion and well-differentiated lesion and being able to respond to progestin,the treatment of fertility-preserving has been paid more attention.This paper elucidated the strategies of fertility-preserving treatment in young women.
Discussion of fertility-sparing treatment and ovarian preservation management for endometrial cancer

Dengfeng Wang,Guonan Zhang

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2015.01.003

2015-01-01

Abstract:Endometrial cancer is a common gynecological cancer. With the increase of young patients, fertility-sparing management and ovarian preservation become more and more important in the treatment of endometrial cancer. But how to preserve the physiological function of patient safely is a problem awaiting solution right now. Fertility-sparing treatment includes high-dose of progestin, GnRH-a, levonorgestrel-releasing intrauterine device, lesion resection via hysteroscope, et al. Moreover, application of assisted reproductive technology after treatment is also very important. Ovarian preservation means preserve one ovary or both ovaries when we do the hysterectomy. Till now, there are some related studies published, and we have reached common understanding on some fields, such as the effectiveness of high-dose progestin, the importance of follow-up, and the application of assisted reproductive technology. But it is still controversial in indication, the choice of treatment, dose and duration of progestin, necessity of hysterectomy after reproduce and so on.
Fertility preserving treatment of ovarian malignant tumor

Meng Wei,Yongxiu Yang

DOI: https://doi.org/10.3760/cma.j.issn.1673-422X.2016.06.021

2016-01-01

Abstract:As a new type of treatment for ovarian cancer,the fertility sparing surgery is put forward for patients who has fertility requirements and the surgical indication.But the indications and safety are still controversial at present on the international.The operation is based on the traditional surgery way,the retention of the uterus and at least one side of the ovary,and then the corresponding adjuvant chemotherapy and ovarian protection,and choosing the right pregnancy timing based on individual difference,to the excellent oncologic outcomes and the favorable reproductive outcomes.
Clinical Outcomes of Fertility-Sparing Treatments in Young Patients with Epithelial Ovarian Carcinoma

Jun Hu,Li-rong Zhu,Zhi-qing Liang,Yuan-guang Meng,Hong-yan Guo,Peng-peng Qu,Cai-ling Ma,Cong-jian Xu,Bi-bo Yuan

DOI: https://doi.org/10.1631/jzus.b1100166

2011-01-01

Journal of Zhejiang University SCIENCE B

Abstract:Objective To assess the clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma (EOC). Methods A retrospective study of young EOC inpatients (≤40 years old) was performed during January 1994 and December 2010 in eight institutions. Results Data were analyzed from 94 patients treated with fertility-sparing surgery with a median follow-up time of 58.7 months. As histologic grade increased, overall survival (OS) and disease-free survival (DFS) of patients receiving fertility-sparing surgery declined. Neither staging surgery nor laparoscopy of early stage EOC with conservative surgery had a significant effect on OS or DFS. Normal menstruation recommenced after chemotherapy in 89% of the fertility-sparing group. Seventeen pregnancies among twelve patients were achieved by the end of the follow-ups. Conclusions Fertility-sparing treatment for patients with EOC Stage I Grade 1 could be cautiously considered for young patients. The surgical procedure and surgical route might not significantly influence the prognosis. Standard chemotherapy is not likely to have an evident impact on ovarian function or fertility in young patients.
Fertility-sparing treatment of early endometrial cancer

LI Jing,LIN Zhong-qiu

2013-01-01

Abstract:Women with endometrial carcinoma have an excellent chance of a cure by undergoing total hysterectomy with bilateral salpingo-oophorectomy. However, many young patients wish to preserve fertility and radical surgery has an adverse effect on their quality of life. Successful hormonal therapy for the early endometrial carcinoma to preserve fertility has been reported. There is a therapeutic dilemma regarding the conservative management. Based on the FIGO cancer report and NCCN guideline, we analyze current evidence about fertility-sparing treatment.
New perspectives of fertility sparing surgery in ovarian cancer treatment

Jingyi Kong,Wenying Pan,Ying Zhang,Shiqian Zhang

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2015.01.019

2015-01-01

Abstract:For early stage ovarian cancer patients, especially child-bearing period women, the preservation of fertility and gonads endocrine function has become a significant issue. However the proper indication as well as surgical procedure is still partially under debating. Depending on the cumulating of related cases, this review tended to assess correlated/influenced prognosis of patients in different FIGO stage, tumor grade and histological subtype, and discuss implication of comprehensive surgical staging, lymphadenectomy, laparoscopy and adjuvant chemotherapy on survival. As the fact that fertility-sparing treatment remains limited, nevertheless the majority knows little about cancer treatment and further fertility, great effort is still in need.
Fertility Preservation among Young Breast Cancer Patients: A Single-Center Experience in China.

Qi Wan,Ling Han,Jing Liu,Hui Li,Ya Li,Qi-Ming Long,Li Tan,Jun-Jie Li

DOI: https://doi.org/10.1016/j.tjog.2021.07.008

IF: 1.944

2021-01-01

Taiwanese Journal of Obstetrics and Gynecology

Abstract:OBJECTIVE:This study aims to investigate the status of fertility preservation (FP) in young breast cancer patients.MATERIALS AND METHODS:A clinical database of six women with breast cancer who wished to undergo FP before starting chemotherapy were analyzed between January 2018 and December 2019 in our hospital. Among the six women, three were unmarried and three were married.RESULTS:Three patients chose oocyte preservation and obtained 23, 7, and 17 MII oocytes, respectively. One patient chose embryo freezing, and three embryos were frozen. Fertility preservation failed for two patients, one of whom had premature ovulation, while the other patient abandoned egg retrieval on the human chorionic gonadotropin (HCG) day.CONCLUSION:The present results indicate that oocyte and embryo cryopreservation are effective optional methods for young breast cancer patients. However, a lack of knowledge, the urgency of cancer treatment, and financial constraints are causes for a low access rate regarding this process.
[The Fertility-Associated Treatment of Young Breast Cancer Patients].

Yunshu Lu,Kejin Wu

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2016.01.017

2016-01-01

Abstract:There is no treatment norm on the fertility issue of breast cancer patients. The clinical studies show that the effects of chemotherapy and endocrine treatment on menstrual cycle and ovarian function have connection with patients' age, therapeutic regimen and drug dose. The time to be pregnant should be decided according to the stage of tumor and the therapeutic regimen. The trimester of pregnancy and tumor stage should be considered when making the therapeutic regimen for the breast cancer patients during pregnancy. And it is not recommended to choose the induced abortion for the therapeutic aim. Theoretically, ovarian function inhibition drugs have great application prospects, while, of which the long-term affect on human body and the relation with tumor development need more researches to study. The available evidence-based practices consider that the pregnancy after breast cancer treatment has no adverse affects on the prognosis of early and middle stage breast cancer patients. More study results are needed to normalize and detail the therapeutic regimen and fertility guidance.
Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience

Yao Wang,Jia-Xin Yang

DOI: https://doi.org/10.2147/CMAR.S188087

2018-12-07

Abstract:Endometrial cancer (EC) is the most common malignant tumor of the female reproductive tract in developed countries and the second most common gynecologic malignancy in China. Although EC is most often diagnosed in postmenopausal women, the increase in obesity rates and other lifestyle changes has been accompanied by an increase in the prevalence of EC among younger women. Approximately 4% of patients are diagnosed before the age of 40 years and before having given birth. Such patients may have a strong desire to preserve their fertility despite oncologic risks and thus may be reluctant to undergo standard treatment for EC, which includes hysterectomy, bilateral salpingo-oophorectomy, and surgical staging. Therefore, more conservative treatment approaches may need to be discussed, along with their associated oncologic and reproductive outcomes. In fact, various studies have confirmed the effectiveness and safety of conservative treatment in EC. This review aimed to provide a concise yet informative overview of the current status of fertility-preserving treatment for EC in China, as well as to summarize the latest and ongoing research efforts in this area.
Fertility preservation in young breast cancer patients

辛灵,白宇鸽,叶京明,段学宁,程元甲,刘荫华,徐玲,刘倩

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2021.02.007

2021-01-01

Abstract:China's cancer burden is increasing year by year, and breast cancer has the highest incidence among all female malignancies in Chinese women. New cases in China account for 12.2% of all newly diagnosed breast cancer cases worldwide, and deaths account for 9.6% of global breast cancer deaths. Since the National People's Congress Standing Committee voted to pass the amendments to the Population and Family Planning Law on December 27, 2015, the universal two-child policy has made more and more families have childbearing needs. In order to better balance the contradictory problem of the survival and fertility of young breast cancer patients, this article reviews the relevant research at home and abroad. Those studies unanimously observed that women with a history of breast cancer are safe in pregnancy. No reduction in overall survival was observed compared with the non-pregnant group. At the same time, it is safe and feasible to apply fertility protection measures, especially the application of gonadotropin-releasing hormone agonists, to reduce the early risk of menopause and improve fertility prospects. Therefore, clinicians should correctly provide help for breast cancer survivors who have fertility requirements and provide as many opportunities as possible for future pregnancy.
Fertility preservation for patients with cancer

Sanghoon Lee,Tak Kim

DOI: https://doi.org/10.5124/jkma.2022.65.6.329

2022-06-10

Journal of the Korean Medical Association

Abstract:Background: The survival rate of cancer patients is increasing owing to the early diagnosis and treatment methods. Radiotherapy and chemotherapy may cause serious complications, such as ovarian failure and infertility. In particular, preservation of fertility in women of reproductive age with cancer could improve their quality of life as well as reduce social and psychological pain.Current Concepts: Embryo or oocyte cryopreservation is a method of fertility preservation; however, it cannot be utilized by all women with cancer because of the complications of the condition and treatment method. Ovarian tissue cryopreservation and transplantation enables fertility preservation in those needing immediate cancer treatment, such as chemotherapy or radiotherapy, or those unqualified for ovarian stimulation. A recent review reported that frozen-thawed ovarian transplantation led to approximately 130 live births with a conception rate of approximately 30%. Endocrine function recovery occurred in 92.9% of the patients between 3.5 and 6.5 months after transplantation.Discussion and Conclusion: In this study, we introduced various methods and strategies for improving the outcomes of ovarian tissue cryopreservation and transplantation. These results could serve as a reference for patients and clinicians to choose the best options for fertility preservation based on the patient’s current situation and condition.
Fertility preservation and assisted reproductive techniques in cervical disease

Yingxi Wang,Xiumei Zhen,Jie Qiao

DOI: https://doi.org/10.3760/cma.j.issn.2096-2916.2019.03.012

2019-01-01

Abstract:With the popularization of cervical cancer screening and the delay of women's reproductive age,more and more women were found cervical disease before childbirth.Different treatments can be performed according to their condition,including the age of the patients,the specific stage of cervical cancer or cervical intraepithelial neoplasia and the demand of fertility.After receiving the treatment of cervical disease,some women can be infertile.They can increase the chance of pregnancy with the help of assisted reproductive technology.The safety and efficacy of assisted reproductive technology in patients with cervical lesions and cervical cancer need further large sample studies.
Fertility preservation and infertility treatment in breast cancer patients

Edgar Petru

DOI: https://doi.org/10.1007/s10354-010-0833-y

Abstract:About 12% of breast cancer cases occur before the age of 35 years. Thus, young patients may consider preservation of ovarian function during cytotoxic therapy and/or childbearing after treatment. Besides the exposure to cytotoxic agents over several months, a significant number of patients will need sequential antihormonal therapy for years. Thus, even young patients at diagnosis may have to postpone pregnancy for years. At that time, the probability of pregnancy may per se be considerably reduced. Young patients per se carry a worse prognosis compared to their postmenopausal counterparts. Ovaries may harbor viable tumor cells. Premenopausal patients have a higher prevalence of BRCA gene mutation than older patients. Thus, even if the ovaries are preserved, the risk of developing cancer in the ovary may be high. Normal menstrual cyclicity after chemotherapy/antihormonal therapy does not preclude premature ovarian failure. After antineoplastic therapy, it is recommended to wait at least for two months before the evaluation of the ovarian function. The most reliable parameter to assess the ovarian reserve is the anti-muellerian factor (AMH; Muellerian Inhibiting Factor, MIF). Four randomized studies have investigated the protective effect of the GnRH analogue goserelin on ovarian function. Due to the inconsistent results observed, the concurrent administration of GnRH analogues with cytostatic chemotherapy now has to be considered experimental and cannot be recommended. Emergency in vitro fertilization may be performed between breast cancer diagnosis and the start of chemotherapy in selected cases. Extracorporal in vitro fertilization may be performed and the resultant embryo cryopreserved to preserve fertility.
Offer protection to individual physiological and reproductive function in treatment of cervical cancer with view and technique of oncofertility

Heng Cui,Hongyan Cheng,Qun Lu

DOI: https://doi.org/10.3877/cma.j.issn.1673-5250.2015.04.001

2015-01-01

Abstract:The incidence and the cure rate of young cancer patients are rising,while surgery, radiation and chemotherapy often bring different degrees of damage to the reproductive function.It becomes more and more urgent to keep and preserve the reproductive functions of young cancer patients.Oncofertility arises at the historic moment. Oncofertility is to reduce the infertility risk caused by treatment and intervention methods,providing opportunities for the choice of patients to have a higher quality of life on the base of reducing and preventing the risk of tumor recurrence and the resulting death,prolonging patients′survival time,and even a cure for cancer.The main methods to save and protect the reproductive function of women with tumors include ovarian transposition/gonad shielding,application of gonadotropin-releasing hormone analogues (GnRHa)to protect ovarian function in chemotherapy,embryo freezing,egg freezing, ovarian tissue/ovary cryopreservation and transplantation,stem cell differentiation,artificial ovary,uterus transplant engineering,etc..Methods of preservation of reproductive function in cervical cancer treatment include cervical radical trachelectomy (RT),conization of cervix,etc..In addition,radical hysterectomy can keep nerve and vagina lengthening,also may carry on the protection of physiological function in cervical cancer treatment,in effective control of tumor at the same time improving the quality of patients′life.
Analysis of Prognostic Factors of Malignant Ovarian Tumor after Fertility-Preserving Treatment

Ding-yuan Zeng,Keng Shen,Hui-fang Huang,Ming Wu,Ling-ya Pan,Jia-xin Yang,Jing-he Lang

DOI: https://doi.org/10.3760/j:issn:0376-2491.2005.36.016

2005-01-01

Abstract:OBJECTIVE:To explore the prognostic factors of malignant ovarian tumor after fertility-preserving treatment.METHODS:189 patients with malignant ovarian tumor who had undergone fertility-preserving management in the past 20 years were retrospectively analyzed. The correlative factors for survival, recurrence and reproductive status were evaluated. Among the patients, 136 cases suffered from ovarian germ cell tumor (OGCT), 31 cases suffered from ovarian sex cord-stromal tumor (OSCST), and 22 cases suffered from epithelial ovarian cancer (EOC). The median follow-up time of different groups was 50 months for OGCT, 46 months for OSCST, 45 months for EOC respectively.RESULTS:The 5-year survival rates for OGCT, OSCST and EOC groups were 94.0% (131/134), 77.1% (26/30) and 64.7% (16/21) respectively. The recurrent rates were 29.9% (40/134), 20.0% (6/30) and 47.6% (10/21) respectively. 46 babies were delivered during the follow-up period. Standard chemotherapy was the most important prognostic factor for OGCT. FIGO stage and standard chemotherapy were favourable factors for prognosis in OSCST group. The important prognostic factors included FIGO stage and standard comprehensive surgical staging for EOC.CONCLUSION:Fertility-preserving treatment should be considered for OGCT without limitation of FIGO stage, whereas it should be performed individually for OSCST and EOC. The treatment outcome for OGCT is the best, for EOC the worst.
Reproductive Advance of Fertility Preservation in Patients with Early Endometrial Carcinoma or Endometrial Atypical Hyperplasia

Jiao Yu,Yangyang Zhang,Huixia Yang,Yang Xu

DOI: https://doi.org/10.1016/j.gocm.2022.10.005

2022-01-01

Gynecology and Obstetrics Clinical Medicine

Abstract:Endometrial cancer (EC) is the fourth common cancer in women worldwide with its incidence rising each year. 10%–15% young patients are diagnosed of EC. For patients of childbearing age with early endometrial cancer or atypical hyperplasia, it is necessary to consider surgical removal of uterus after they have given birth. It is a big challenge for reproductive doctors and oncologists to help such patients get pregnant safely as soon as possible. In this article, we will review the latest progress in conservative treatment and candidates for fertility preservation, application of molecular detection, the fertility outcome and follow-up treatment which aims to stimulate more thinking.

Fertility preservation treatment in patients with epithelial ovarian cancer

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant—a Chinese retrospective cohort study among 148 cases

Fertility Preservation in Young Female Cancer Patients

Feasibility and Safety of Fertility Preservation Surgery in Female Patients with Early Epithelial Ovarian Cancer

Fertility-preserving treatment for young women with early-stage endometrial cancer

Discussion of fertility-sparing treatment and ovarian preservation management for endometrial cancer

Fertility preserving treatment of ovarian malignant tumor

Clinical Outcomes of Fertility-Sparing Treatments in Young Patients with Epithelial Ovarian Carcinoma

Fertility-sparing treatment of early endometrial cancer

New perspectives of fertility sparing surgery in ovarian cancer treatment

Fertility Preservation among Young Breast Cancer Patients: A Single-Center Experience in China.

[The Fertility-Associated Treatment of Young Breast Cancer Patients].

Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience

Fertility preservation in young breast cancer patients

Fertility preservation for patients with cancer

Fertility preservation and assisted reproductive techniques in cervical disease

Fertility preservation and infertility treatment in breast cancer patients

Offer protection to individual physiological and reproductive function in treatment of cervical cancer with view and technique of oncofertility

Analysis of Prognostic Factors of Malignant Ovarian Tumor after Fertility-Preserving Treatment

Reproductive Advance of Fertility Preservation in Patients with Early Endometrial Carcinoma or Endometrial Atypical Hyperplasia